The Motley Fool

Should I Invest In AstraZeneca Plc?

To me, capital growth and dividend income are equally important. Together, they provide the total return from any share investment and, as you might expect, my aim is to invest in companies that can beat the total return delivered by the wider market.

To put that aim into perspective, the FTSE 100 has provided investors with a total return of around 3% per annum since January 2008.

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...

Quality and value

If my investments are to outperform, I need to back companies that score well on several quality indicators and buy at prices that offer decent value.

So this series aims to identify appealing FTSE 100 investment opportunities and today I’m looking at AstraZeneca (LSE: AZN) (NYSE: AZN.US), the pharmaceutical company.

With the shares at 3154p, AstraZeneca’s market cap. is £39,490 million.

This table summarises the firm’s recent financial record:

Year to December 2008 2009 2010 2011 2012
Revenue ($m) 31,601 32,804 33,269 33,591 27,973
Net cash from operations ($m) 8,742 11,739 10,680 7,821 6,948
Adjusted earnings per share (cents) 510 632 671 728 641
Dividend per share (cents) 205 230 255 280 280

It’s hard to be cheerful about AstraZeneca’s 12% revenue decline and 21% fall in core operating profit during the first quarter. The well-flagged loss of exclusivity on several of its core drugs is to blame; names such as Seroquel IR, Atacand and Crestor have all found themselves exposed to generic competition as patents expire, and it’s hurting the company’s performance, a situation expected to continue through the year as the firm predicts, “mid-to-high single digit decline in revenue on a constant currency basis.”

One bright spot in the quarter-time results is a reassuring 9% upwards thrust in emerging-markets revenue. Around 21% of sales came from countries classified as ’emerging’, which is a figure large enough to be significant. Perhaps such up-and-coming economies can flower to deliver salvation for AstraZeneca, it’s certainly a possibility, and the firm is fighting back on several fronts to reignite its sales with targeted in-house research & development, and an active acquisition programme aimed at picking up often cash-exhausted drug development minnows that find themselves on the cusp of a mass-commercialisation breakthrough with their new formulations.

All in all, AstraZeneca is working hard on its drug pipeline ready to fuel its next growth spurt. Meanwhile, cash generation is holding up to support activities, including the tempting-looking dividend, which is at least some short-term consolation to hungry total-return seekers.

AstraZeneca’s total-return potential

Let’s examine five indicators to help judge the quality of the company’s total-return potential:

1. Dividend cover: adjusted earnings covered last year’s dividend around 2.3 times.  4/5

2. Borrowings: net debt is around 32% of the level of operating profit. 4/5

3. Growth: revenue, earnings and cash flow were all down last year; growth has stalled.  1/5

4. Price to earnings: a forward 10 looks ahead of current growth and yield expectations.  2/5

5. Outlook: recent trading is down; the outlook is cautiously optimistic, longer term.  2/5

Overall, I score AstraZeneca 13 out of 25, which inclines me to caution with regard to the firm’s market-outperformance credentials, going forward.

Foolish summary

Under-control borrowings and decent dividend cover are both reassuring. Negative growth and a lacklustre outlook combine to make the valuation seem generous. I’m keeping AstraZeneca on my watch list for now, despite the forward dividend yield, which is running at about 5.7%.

But at least one well-known, outperforming investor is an AstraZeneca believer. The firm is one of 8 Income Plays Held By Britain’s Super Investor. This report analyses the £20bn portfolio of legendary high-yield expert Neil Woodford and is free for a limited time. To discover the other seven of his favourite dividend growth selections, I recommend you click here

> Kevin does not own shares in AstraZeneca.

“This Stock Could Be Like Buying Amazon in 1997”

I'm sure you'll agree that's quite the statement from Motley Fool Co-Founder Tom Gardner.

But since our US analyst team first recommended shares in this unique tech stock back in 2016, the value has soared.

What's more, we firmly believe there's still plenty of upside in its future. In fact, even throughout the current coronavirus crisis, its performance has been beating Wall St expectations.

And right now, we're giving you a chance to discover exactly what has got our analysts all fired up about this niche industry phenomenon, in our FREE special report, A Top US Share From The Motley Fool.

Click here to claim your copy now — and we’ll tell you the name of this Top US Share… free of charge!